Sage Journals: Discover world-class research

Abstract

Mayer KH, Loo S, Crawford PM, et al. Excess clinical comorbidity among HIV-infected patients accessing primary care in US community health centers. Public Health Rep. 2018;133:109-118. (Original DOI: 10.1177/0033354917748670)

In the above referenced article, Table 3 was published with duplicate information in the initial OnlineFirst version. The correct Table 3 is given below. The article, as published in volume 133, issue 1, reflects the corrected table.

Table 3.
Unadjusted prevalence, estimated marginal prevalence, and odds ratios of clinical conditions among HIV-infected and HIV-uninfected adult patients seen in community health centers, Community Health Applied Research Network database, 2006-2014^a

HIV-Infected Patients (n = 12 837) HIV-Uninfected Patients (n = 227 012)

Condition Unadjusted Prevalence, No. (%) Estimated Marginal Prevalence, %^b Unadjusted Prevalence, No. (%) Estimated Marginal Prevalence, %^b OR (95% CI)^c

Diabetes 2249 (17.5)^d 19.8 36 799 (16.2) 16.5 1.31 (1.22-1.41)

Chronic kidney disease 613 (4.8)^d 14.3 10 675 (4.7) 5.9 4.75 (4.23-5.34)

Hypertension 5604 (43.7)^d 44.2 81 489 (35.9) 39.1 1.38 (1.31-1.46)

Dyslipidemia 5505 (42.9)^d 56.1 94 192 (41.5) 41.6 2.30 (2.17-2.43)

HPV-related cancer 104 (0.8)^d 1.1 576 (0.3) 0.2 5.05 (3.77-6.78)

Lymphoma 69 (0.5)^d 0.5 303 (0.1) 0.1 4.02 (2.86-5.67)

Other cancer 491 (3.8)^d 3.6 6980 (3.1) 2.9 1.25 (1.10-1.42)

Stroke 184 (1.4)^d 1.5 2502 (1.1) 1.2 1.32 (1.06-1.63)

Myocardial infarction 51 (0.4) 0.5 858 (0.4) 0.4 1.06 (0.73-1.54)

Coronary artery disease 79 (0.6) 1.1 2369 (1.0) 0.9 1.30 (0.95-1.77)

Abbreviations: HIV, human immunodeficiency virus; HPV, human papillomavirus; OR, odds ratio.

^aData source: Community Health Applied Research Network Data Warehouse version 3, May 2016.¹⁵

^bThe estimated marginal prevalence represents average prevalence after adjusting for covariates and accounting for the random effect of clinic (ie, the clustering of patients within a clinic).

^cMultilevel logistic regression models controlled for age, race/ethnicity, and sex and accounted for clustering of patients within community health centers. Models also considered body mass index as well as opioid use, hepatitis C virus infection, and alcohol use.

^d P ≤ .002 comparing unadjusted prevalences of HIV-infected vs HIV-uninfected patients.

	HIV-Infected Patients (n = 12 837)		HIV-Uninfected Patients (n = 227 012)
Condition	Unadjusted Prevalence, No. (%)	Estimated Marginal Prevalence, %^b	Unadjusted Prevalence, No. (%)	Estimated Marginal Prevalence, %^b	OR (95% CI)^c
Diabetes	2249 (17.5)^d	19.8	36 799 (16.2)	16.5	1.31 (1.22-1.41)
Chronic kidney disease	613 (4.8)^d	14.3	10 675 (4.7)	5.9	4.75 (4.23-5.34)
Hypertension	5604 (43.7)^d	44.2	81 489 (35.9)	39.1	1.38 (1.31-1.46)
Dyslipidemia	5505 (42.9)^d	56.1	94 192 (41.5)	41.6	2.30 (2.17-2.43)
HPV-related cancer	104 (0.8)^d	1.1	576 (0.3)	0.2	5.05 (3.77-6.78)
Lymphoma	69 (0.5)^d	0.5	303 (0.1)	0.1	4.02 (2.86-5.67)
Other cancer	491 (3.8)^d	3.6	6980 (3.1)	2.9	1.25 (1.10-1.42)
Stroke	184 (1.4)^d	1.5	2502 (1.1)	1.2	1.32 (1.06-1.63)
Myocardial infarction	51 (0.4)	0.5	858 (0.4)	0.4	1.06 (0.73-1.54)
Coronary artery disease	79 (0.6)	1.1	2369 (1.0)	0.9	1.30 (0.95-1.77)

Erratum

Abstract